skip to Main Content

2021 Statements

Time for $5 Coalition Statement: Cepheid’s Updated GeneXpert Pricing Does Not Address Country Needs
May 10, 2021 — The Time for $5 Coalition, comprised of over 150 civil society organizations globally, calls out Cepheid for the company’s insufficient and self-serving GeneXpert pricing packages for low- and middle-income countries (LMICs), announced May 6, 2021.

TAG Welcomes U.S. Government Support of Intellectual Property Flexibilities to Enable COVID-19 Vaccine Access
May 6, 2021 — Treatment Action Group (TAG) applauds the U.S. government’s decision to support the India-South Africa proposed waiver of certain intellectual property rights to enable equitable access to life-saving interventions for COVID-19.

Landmark TB Trials Results Published in New England Journal of Medicine
May 6, 2021 — Today the New England Journal of Medicine published results of a landmark phase III clinical trial that found a 4-month regimen containing rifapentine and moxifloxacin performed as well as the six-month standard regimen in curing drug-susceptible pulmonary TB.

Community Movements Across Africa, Asia and South America Celebrate Roll-Out of Short-Course, Patient-Friendly TB Preventive Therapy
February 16, 2021 — Advocates and affected communities working towards the global scale-up of short-course TB preventive therapy (TPT) hail the recent announcement of the launch of decently priced, patient-friendly fixed-dose combinations (FDC) of 3HP in five high burden HIV and TB countries.

Harnessing the COVID-19 Response Towards Hepatitis C Elimination
February 1, 2021 — On Wednesday, February 3, 2021, Treatment Action Group, Médecins du Monde, hepCoalition, and the UNITE network convene a virtual policy dialogue among parliamentarians, global civil society organizations, and community leaders to share how COVID-19 has impacted global hepatitis C virus (HCV) elimination efforts.

Back To Top